ArticleJournal of cosmetic dermatology2025
Identification of Proteomic Biomarkers and Therapeutic Targets for Vitiligo Using a Two-Sample Proteome-Wide Mendelian Randomization Approach.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Proteomic Biomarkers and Therapeutic Targets for Vitiligo Using a Two-Sample Proteome-Wide Mendelian Randomization Approach.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVitiligo is a chronic autoimmune disorder characterized by melanocyte loss and depigmented skin patches. Effective treatment options are limited, and therapeutic progress has been hindered by incomplete understanding of its precise pathogenic mechanisms. We aimed to identify candidate protein biomarkers and therapeutic targets for vitiligo by integrating large-scale proteomics and genomic data using Mendelian randomization (MR).
methodsUsing two-sample MR analysis, we leveraged genome-wide association study (GWAS) data for vitiligo (131 cases and 207 482 controls of European descent) and proteomic data comprising 4907 plasma proteins from the Decode cohort (35 559 participants). Causal relationships between genetically predicted plasma protein levels and vitiligo risk were evaluated through five complementary MR methods, along with enrichment analyses to explore their biological implications. Further validation was conducted via independent transcriptomic datasets, single-cell RNA sequencing, and molecular docking analysis to identify potential therapeutic compounds.
resultsWe identified seven proteins (HEPHL1, PRDX1, DEFA1, CSGALNACT2, HERC4, NDC80, and SPHK2) causally associated with vitiligo risk. Notably, HERC4 and NDC80 exhibited robust expression in vitiligo lesions across validation datasets. Functional enrichment analysis implicated these proteins in oxidative stress regulation, immune modulation, and cellular signaling pathways. Molecular docking analyses further highlighted potential therapeutic agents, including zoledronic acid and gramine.
conclusionsOur integrative MR analysis identified novel protein biomarkers and promising therapeutic targets for vitiligo, particularly HERC4 and NDC80. These findings offer potential opportunities for improved diagnosis and the development of targeted therapies, advancing precision medicine approaches for vitiligo management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.